Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> Ausstellungen und Veranstaltungen > Unsere Webinare ansehen >
[FMP-filiale::haut]
Bioprinting and Spheroids Webinar

Thursday, 21 May 2026 • 3:30 PM CET

Bioprinting and primary spheroids: autologous 3D platforms for long-term immuno-oncology screening

This presentation details the development of sophisticated 3D platforms combining precision 3D bioprinting with spheroid assembly. Developed exclusively from patient-derived primary cells, these models integrate tumor, immune, and healthy components (hepatocytes, fibroblasts) to faithfully replicate the tumor microenvironment.

Given their long-term viability (spanning several months), these platforms serve as cutting-edge predictive screening tools to evaluate the efficacy, penetration, and toxicity of next-generation biotherapies.

Join Our Exclusive Live Webinar

Register Now – Secure Your Spot

21 May 2026 • 3:30 PM CET • Live via Zoom

Meet the Speaker

Clément MILET

Clément MILET

Laboratory and Quality Director, CTIBIOTECH
Head of the 3D Bioprinting Programme

Clément MILET joined CTIBIOTECH in 2017 to lead the 3D bioprinting programme, building on the organisation's existing capabilities in 3D cell and tissue culture. His previous experience at the Institute of Advanced Biosciences (Grenoble) and at the Lyon Cancer Research Centre (CRCL) has given him deep expertise in 3D cancer models. Since 2020, he has been Laboratory and Quality Director at CTIBIOTECH, overseeing research programmes and expanding production capabilities through 3D bioprinting.

Key Takeaways

  • Autologous 3D Platforms – Precision 3D bioprinting combined with spheroid assembly, built exclusively from patient-derived primary cells, integrating tumor, immune, and healthy components (hepatocytes, fibroblasts) to faithfully replicate the tumor microenvironment.
  • Long-Term Viability – Platforms maintaining viability over several months, enabling extended studies that go beyond the limitations of conventional short-term in vitro models.
  • Predictive Screening for Biotherapies – 3D models serving as predictive screening tools to evaluate the efficacy, penetration, and toxicity of next-generation biotherapies in immuno-oncology.

Registration is free but required.
We look forward to welcoming you on 21 May 2026 at 3:30 PM CET.

Register for the Webinar

[FMP-filiale::bas]